Related Experiment Video
Updated: Oct 26, 2026
Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
Asciminib After Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia: A Multicenter
Yulia Vlasova1, Nikita Volkov1, Elena Morozova1
1RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation.
Introduction:
Asciminib, a first-in-class STAMP inhibitor, has demonstrated efficacy in chronic-phase chronic myeloid leukemia (CML) after failure of prior TKIs (tyrosine kinase inhibitor), including T315I-mutated disease. However, data on its use after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited to small case series.
Patients And Methods:
We conducted a multicenter retrospective analysis of 22 patients with CML who received asciminib after allo-HSCT performed between August 2021 and November 2025. The primary objectives were to assess outcomes, molecular response rates, safety, and tolerability.
Results:
The median number of prior TKIs was 3 (range, 2-4). BCR::ABL1 kinase domain mutations were present in 15 patients (68%), with T315I in 12 (55%). Asciminib was started at a median of 2.4 months (range, 0.6-24) after HSCT at doses of 20 to 80 mg daily, with dose reductions required in 6 patients (27.3%) due to cytopenias or graft hypofunction. With a median follow-up of 28 months from asciminib initiation, the estimated 3-year overall survival was 81% (95% CI, 56-92), and progression-free survival was 76% (95% CI, 51-89). Molecular response 5-log reduction (MR5) was achieved in 19 of 22 patients (86.4%). The only grade 3-4 toxicity was thrombocytopenia, which occurred in 4 patients (18.2%).
Conclusions:
Low-dose asciminib (20-80 mg daily) was generally feasible and well tolerated after allogeneic HSCT, including in patients with the T315I mutation and graft hypofunction, and MR5 was achieved in most patients. Asciminib may represent a promising option for post-transplant disease control, but confirmation in prospective, controlled studies is required.
